IMIPRAMINE RELAPSE PREVENTION IN DEPRESSED METHADONE PTS

预防抑郁型美沙酮患者丙咪嗪复发

• 批准号: 2733554
• 负责人: SUSAN TROSS
• 金额: $ 77.18万
• 依托单位: ST. LUKE'S ROOSEVELT HOSP CTR (NEW YORK)
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-09-01 至 2000-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2733554
• 关键词: behavior prediction; behavioral /social science research tag; clinical depression; clinical research; cognitive behavior therapy; combination chemotherapy; combination therapy; drug abuse chemotherapy; drug abuse prevention; drug addiction; human subject; human therapy evaluation; imipramine; longitudinal human study; mental disorder chemotherapy; methadone; opiate alkaloid; relapse /recurrence; social support network

APPLICANT'S ABSTRACT: This is a revised version of the previously submitted application, #ROI DA09583-01, also entitled Imipramine+Relapse Prevention in Depressed Methadone Pts. Relapse prevention is a widely used cognitive-behavioral skills training approach to the problem of initiating and maintaining drug use abstinence. Imipramine has been shown to have strong antidepressant effects and significant, but qualified, effects on self-reported drug use among depressed cocaine-using methadone patients. Among this substantial subgroup of patients, there are no studies of the efficacy of combination pharmacotherapeutic and psychotherapeutic approaches to the problem of cocaine use. This study will examine the question of whether adding relapse prevention group to imipramine is more effective than imipramine alone in reducing cocaine use among 252 inner-city depressed methadone patients who use cocaine. It will have the methodological advantages of: (1) including a non-specific psychological intervention comparison condition (i.e. support group); and (2) targeting a sample with rigorously diagnosed DSM-IV depressive disorders. It will have the important clinical advantage of using a manualdriven relapse prevention protocol -- that will draw from two programs with demonstrated efficacy. This study will also assess the impact of potential predictors on intervention effects on cocaine use, especially severity of cocaine use and severity of depression. It will also assess the impact of potential mediators, representing acquisition of intervention components, on intervention effects on cocaine use, especially: level of relapse prevention skill and perceived self-efficacy to use these skills. Patients will be assessed on repeated measures of cocaine use and depression at: baseline, end of psychological intervention (at 3 months), end of imipramine maintenance (at 6 months) and 3-month post-intervention follow-up (at 9 months).

申请人的摘要： 这是先前提交的应用程序#ROI的修订版 DA09583-01，也标题为ipramine+Repapse预防抑郁症 美沙酮PT。预防复发是一种广泛使用的认知行为 技能培训方法解决和维护药物的问题 使用禁欲。 丙咪嗪已被证明具有较强的抗抑郁药 效果和对自我报告的药物使用的重要影响，但有资格的影响 在抑郁的可卡因美沙酮患者中。 在这个实质性中 患者亚组，没有关于组合功效的研究 药物治疗和心理治疗方法 可卡因使用。 这项研究将研究是否增加复发的问题 预防丙咪嗪比单独的丙咪嗪更有效 在252名城市抑郁美沙酮患者中减少可卡因的使用 使用可卡因。 它将有 方法论上的优势：（1）包括非特异性心理学 干预比较条件（即支持小组）； （2）针对 患有严格诊断的DSM-IV抑郁症的样本。 它将有 使用手动驱动复发预防的重要临床优势 协议 - 这将从具有证明功效的两个程序中获取。 这项研究还将评估潜在预测因子对 干预对可卡因使用的影响，尤其是可卡因使用的严重程度 抑郁的严重程度。 它还将评估潜力的影响 代表采集干预组件的调解人 干预对可卡因使用的影响，特别是：复发水平 使用这些技能的预防技能和自我效能感。 患者 将根据可卡因使用和抑郁的重复措施进行评估： 基线，心理干预的结束（在3个月时），咪帕明的末端 维护（在6个月时）和3个月后进行后随访（9点 几个月）。